Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Enobosarm, also formerly known as ostarine and by the developmental code names GTx-024, MK-2866, and S-22, is a selective androgen receptor modulator (SARM) which is under development for the treatment of androgen receptor-positive breast cancer in women and for improvement of body composition (e.g., prevention of muscle loss) in people taking GLP-1…
History, Community, Culture & Research
Explore the main themes, entities and connections around Enobosarm. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
effects muscle clinical trials doses mg like testosterone sarms day drug phase development also levels anabolic cancer prostate may women
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Enobosarm | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Enobosarm | ATC code | None | 1.00 | infobox |
| Enobosarm | Bioavailability | 100% (rats) | 1.00 | infobox |
| Enobosarm | CAS Number | 841205-47-8 | 1.00 | infobox |
| Enobosarm | ChEMBL | ChEMBL1738889 | 1.00 | infobox |
| Enobosarm | ChemSpider | 9501667 | 1.00 | infobox |
| Enobosarm | CompTox Dashboard (EPA) | DTXSID30233006 | 1.00 | infobox |
| Enobosarm | DrugBank | DB12078 Y | 1.00 | infobox |
| Enobosarm | Elimination half-life | 14–24 hours | 1.00 | infobox |
| Enobosarm | Excretion | Feces (70%), urine (21–25%) (rats) | 1.00 | infobox |
| Enobosarm | Formula | C19H14F3N3O3 | 1.00 | infobox |
| Enobosarm | KEGG | D10221 | 1.00 | infobox |
| Enobosarm | Legal status | US: Investigational New Drug | 1.00 | infobox |
| Enobosarm | Melting point | 132 to 136 °C (270 to 277 °F) | 1.00 | infobox |
| Enobosarm | Metabolism | CYP3A4, UGT1A1, UGT2B7 | 1.00 | infobox |
| Enobosarm | Metabolites | Enobosarm glucuronide | 1.00 | infobox |
| Enobosarm | Molar mass | 389.334 g·mol−1 | 1.00 | infobox |
| Enobosarm | Other names | Ostarine; GTx-024; MK-2866; S-22; VERU-024 | 1.00 | infobox |
| Enobosarm | PDB ligand | RLJ (PDBe, RCSB PDB) | 1.00 | infobox |
| Enobosarm | PubChem CID | 11326715 | 1.00 | infobox |
| Enobosarm | Routes of administration | By mouth | 1.00 | infobox |
| Enobosarm | UNII | O3571H3R8N | 1.00 | infobox |
| Enobosarm | is a | nonsteroidal SARM | 0.90 | text |
| Enobosarm | is a | substrate of CYP3A4 and UGT enzymes.The metabolism of enobosarm is similar to that of the closely structurally related drug bicalutamide.EliminationIn rats | 0.90 | text |
| Enobosarm | is a | substrate of CYP3A4 and UGT enzymes.The metabolism of enobosarm is similar to that of the closely structurally related drug bicalutamide | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.